Italia markets close in 5 hours 4 minutes

Arbutus Biopharma Corporation (0SGC.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,0000+0,1091 (+5,77%)
Al 03:09PM BST. Mercato aperto.
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

    Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161 Extending cash runway through Q3 2025 WARMINSTER, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that tar

  • GlobeNewswire

    Arbutus to Participate in Two Upcoming Investor Conferences

    WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference: Formal Presentation on September 12, 202

  • GlobeNewswire

    Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

    Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase 2a clinical trial, was generally well tolerated and appears to result in continued HBsAg declines in some patients First patient dosed in additional arm of Phase 2a clinical trial combining imdusiran, VTP-300, NA therapy and nivolumab – advancing towards goal of fur